WO1986002350A1 - Ultra violet agents - Google Patents

Ultra violet agents Download PDF

Info

Publication number
WO1986002350A1
WO1986002350A1 PCT/AU1985/000242 AU8500242W WO8602350A1 WO 1986002350 A1 WO1986002350 A1 WO 1986002350A1 AU 8500242 W AU8500242 W AU 8500242W WO 8602350 A1 WO8602350 A1 WO 8602350A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
alkyl
methyl
compounds
amino
Prior art date
Application number
PCT/AU1985/000242
Other languages
French (fr)
Inventor
Walter Clark Dunlap
Bruce Edward Chalker
Original Assignee
Australian Institute Of Marine Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Australian Institute Of Marine Science filed Critical Australian Institute Of Marine Science
Publication of WO1986002350A1 publication Critical patent/WO1986002350A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/112Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C07D295/116Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings with the doubly bound oxygen or sulfur atoms directly attached to a carbocyclic ring

Definitions

  • THIS INVENTION relates to a new and useful class of ultra violet light absorbing compounds and to their use in sunscreen compositions and the protection of paint films and plastics materials from solar degradation.
  • UV agents Chemical compounds which absorb light in the ⁇ V portion of the spectrum
  • sunscreen agents have a number of important commercial applications. The best known of these are probably their use as sunscreen agents to protect the skin from the erythermal effect of sunlight and to shield paint films and plastics materials from solar degradation. They have also been used elsewhere as, for example, as energy transfer means in UV light crosslinking of certain polymers.
  • Common commercially available UV agents include for example, para amino benzoic acid derivatives, benzotriazoles, benzophenones, methoxycinnamates and salicylates. It has also been proposed, for example in United Kingdom Patent Application 2 , 120, 549 A, that certain vinylogous amide compounds may also be used as sunscreen agents.
  • UV agents exhibit strong radiation absorption in the UV region, the actual value of the absorption maximum being important in relating the compounds to their intended end use.
  • human skin is particularly sensitive to damage at wavelengths between about 290-320 nm (nanometer), the so-called UV-B region, with some likely carryover of harmful effects into the wavelength in excess of 320 nm, the UV-A region.
  • UV agents used to protect plastics and paint films commonly have absorption maxima in the region of 340-355 nm and higher.
  • UV agents for commercial purposes will have absorption maxima in excess of about 290 nm. They should also have acceptable permanence, stability and compatibility with media to which they are to be applied or incorporated. In particular, when the UV agents are to be used on living tissue, they must be non-toxic and not otherwise harmful to the host surface. These various criteria are often in conflict and limit the choice of UV agents available for specific end uses. Furthermore, the final selection, when it is made, is often a compromise in which for example, efficacy must be sacrificed for stability or freedom from toxic side-effects.
  • the chromophore has the structure:
  • the oxygen subsitutent at the 2 position is fundamental to the UV absorption characteristics UV compounds of the invention.
  • certain compounds containing the above chromophore have an absorption maximum at 305-340 nm.
  • analogous carbonylsare prepared in which there is no oxygen function at the 2 position e.g. ethyl 3-octylamino-2-butencate
  • the absorption maximum drops to about 285 nm, which is significantly below the abovementioned useful absorption range achieved by UV compounds of this invention.
  • Preferred novel UV absorbing compounds of the invention, which are particularly useful in sunscreens are of formula (2) or (3) below:
  • R 1 is selected from hydrogen, alkyl or alkenyl
  • NR 2 is an amino group or a secondary or tertiary amine moiety in which the N atom bears either one or two unsubstituted or substituted alkyl, aryl or alkenyl groups which may be the same or different when two are present;
  • R is a moiety selected from alkyl, substituted alkyl, hydroxyl, carboxylic acid, ester or ether at positions 4, 5 or 6 on the ring;
  • n 0-4.
  • the oxygen atom at the 2- position on the ring structure is a characteristic feature of all of our novel compositions.
  • R 1 When the substituent R 1 is alkyl or alkenyl, it may be a straight or branched chain, which in turn may bear further substituent groups or be interrupted by a hetero-atom.
  • R 1 may be methyl, ethyl, propyl, methoxy methyl or methoxy ethyl. It may also be cyclic, for example it may be cyclohexly.
  • Our most preferred compositions are those in which R 1 is an alkyl chain containing 1 - 4 carbon atoms.
  • -NR 2 is a amino group.
  • One or both of the hydrogen atoms of that group may be replaced as described hereinabove by the same or different substituents selected from alkyl, aryl or alkenyl groups, which may themselves be branched, linear or contain a cyclical structure.
  • the selected substituent may itself contain a further substituent.
  • the substituent groups may together form a carbocyclic or heterocyclic ring system.
  • suitable components -NR 2 are, for example, cyclohexylamino, anilino, undecylamino, hexylamino, octylamino, decylamino, heptylamino, benzylamino, octadecylamino, pentylamino, nonylamino, N-methyl-N-benzylamino, di-butylamino, N-morpholino dodecylamino, phenethylamino, 1,1,3,3 tetramethyl butylamino, N-pyrolidinyl, N-piperidenyl, di-butylamino, N-methyl-N-cyclohexylamino, components of the structures -NHCH 2 COOCE 3 , -NHCH (CH 3 )COOCH 3 , -NHCH(CH 2 OH)COOCH 3 and -NHCH(HO-4-C 6 H 4 )COOC
  • -NR 2 is alkylamino, arylamino, amino acid and amino acid ester.
  • -NR 2 be a disubstituted amino.
  • composition of the component R when present is not usually critical and it is chosen with regard to such factors as, for example, the required solubility of hydrophilic/lipophilic balance of the molecule as a whole.
  • suitable components R are, for example, alkyl, substituted alkyl, hydroxyl, alkoxy, carboxylic acid ester or ester moieties. That is R may be, for example, 5-hydroxyl, 5 carboxylic acid or ester thereof, 5-hydroxymethyl, 5,5-dimethyl, 5-t-butyl and 4,4,6,6-tetramethyl.
  • compositions are those in which the component R when present, is methyl or ethyl.
  • the compounds (4c) below may be prepared by an appropriate standard method of organic synthesis.
  • Compounds (4a) are acidic and can be alkylated at the 2-hydroxyl group with suitable alkylating agents such as dialkyl sulphates, alkyl tosylates or diazoalkanes (when there is no 3-hydroxyl) to give the alkyl derivatives (4b).
  • suitable alkylating agents such as dialkyl sulphates, alkyl tosylates or diazoalkanes (when there is no 3-hydroxyl) to give the alkyl derivatives (4b).
  • Compounds (4b) can be reacted with amino compounds to effect a substitution at the 3-position to give compounds (4c).
  • Compounds of structure (4a) may be prepared by a number of routes from various starting materials depending on the desired size and substitution of the carbocycle.
  • UV agents have an absorption maximum in the region of 305-340 nm.
  • the UV compound according to our invention will comprise a six-membered ring as structure (2) since derivatives of the five-membered enaminoketones tend to absorb UV-light in the region of 287-297 nm.
  • sun-screen agents we prefer to use compounds according to structure (2).
  • UV compounds of the invention are readily compounded by the standard methods of the art into, for example, creams or lotions, making use of conventional emollients, emulsifiers, preservatives, anti-oxidants, perfumes and colouring agents.
  • suitable emollients are, mineral oil, squalene, octyl palmitate, cocoa butter, sesame oil, and pristane, either singly or in combination.
  • Typical emulsifiers including for example, polyoxyethylene (3) olyl ether, polyglyceryl-4-oleate and polysorbate 80. The invention is illustrated by the following examples, in which all parts are given by weight.
  • Cyclopentanone (16 g, 0.15 mol) and cupric chloride (240 g, 1.5 mol) were refluxed for 1.5 h in 800 ml of a 50% solution of dioxane in water. This was allowed to cool, then water (400 ml) was added, filtered and extracted 3-5 times with diethyl ether (total 2.0 1). The organic phase was backwashed with water (200 ml), dried over sodium sulphate and evaporated to collect crude product, mp 130°. The crude material was dissolved in a large quantity of dichloromethane, treated with charcoal and filtered. This solution was evaporated to a suspension then filtered to collect the product as pale yellow crystals, mp 140-141°C.
  • 2,3-Dihydroxy-cyclohex-2-enone (15 g) was dissolved in 4N NaOH (45 ml) and cooled to 5°C.
  • Dimethyl sulfate (18 ml; freshly distilled and stored over KOH pellets) was added dropwise with vigorous stirring while maintaining the internal temperature below 10°C.
  • the reaction was maintained above pH 7 throughout the addition while under an atmosphere of nitrogen.
  • a further quantity of 4N NaOH (45 ml) was added after the addition of dimethyl sulfate was completed and the reaction was allowed to stir overnight (16 h) at room temperature.
  • the mixture was cooled to 5°C and acidified to congo red with 4N H 2 SO 4 while still under nitrogen.
  • the resulting yellow solution was evaporated to ca.
  • Example 25 The compounds described in Table 5 and Table 6 below were prepared following essentially the proceedures described in Example 19.
  • Example 25 The compounds described in Table 5 and Table 6 below were prepared following essentially the proceedures described in Example 19.
  • Example 25 The compounds described in Table 5 and Table 6 below were prepared following essentially the proceedures described in Example 19.
  • 2,3-Dihydroxy-cyclohex-2-enone (15 g) was dissolved in ethanol (50 ml) and cooled to 5°C in an ice bath. Aqueous 4NNaOH (45 ml) was added to the ethanolic solution under nitrogen. Diethyl sulfate (22 ml) was added dropwise with vigorous stirring while maintaining the internal temperature below 10°C. The reaction was maintained above pH 7 throughout the addition under an atmosphere of nitrogen. A further quantity of 4N NaOH (45 ml) was added after the addition of diethyl sulfate was completed and the reaction allowed to stir at room temperature for 24 h. The organic solvent was removed under reduced pressure.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

A new and useful class of ultra light absorbing compounds and their use in sunscreen compositions and the protection of paint films and plastics materials from solar degradation. In particular the compounds possess a novel UV absorbing chromophore of structure (I). It has been found that the oxygen substituent at the 2 position is essential to the invention. Preferred compounds of the invention have formulae (I) or (II), wherein R1 is selected from hydrogen, alkyl or alkenyl; NR2 is an amino group or a secondary or tertiary amine moiety in which the N atom bears either one or two unsubstituted or substituted alkyl, aryl or alkenyl groups which may be the same or different when two are present; R is a moiety selected from alkyl, substituted alkyl, hydroxyl, carboxylic acid, ester or ether at positions 4, 5 or 6 on the ring; n is 0-4.

Description

ULTRA VIOLET AGENTS
THIS INVENTION relates to a new and useful class of ultra violet light absorbing compounds and to their use in sunscreen compositions and the protection of paint films and plastics materials from solar degradation.
Chemical compounds which absorb light in the ϋV portion of the spectrum (i.e. UV agents) have a number of important commercial applications. The best known of these are probably their use as sunscreen agents to protect the skin from the erythermal effect of sunlight and to shield paint films and plastics materials from solar degradation. They have also been used elsewhere as, for example, as energy transfer means in UV light crosslinking of certain polymers. Common commercially available UV agents include for example, para amino benzoic acid derivatives, benzotriazoles, benzophenones, methoxycinnamates and salicylates. It has also been proposed, for example in United Kingdom Patent Application 2 , 120, 549 A, that certain vinylogous amide compounds may also be used as sunscreen agents.
All of these UV agents exhibit strong radiation absorption in the UV region, the actual value of the absorption maximum being important in relating the compounds to their intended end use. For example, it is known that human skin is particularly sensitive to damage at wavelengths between about 290-320 nm (nanometer), the so-called UV-B region, with some likely carryover of harmful effects into the wavelength in excess of 320 nm, the UV-A region. On the other hand UV agents used to protect plastics and paint films commonly have absorption maxima in the region of 340-355 nm and higher.
Thus in general, useful UV agents for commercial purposes will have absorption maxima in excess of about 290 nm. They should also have acceptable permanence, stability and compatibility with media to which they are to be applied or incorporated. In particular, when the UV agents are to be used on living tissue, they must be non-toxic and not otherwise harmful to the host surface. These various criteria are often in conflict and limit the choice of UV agents available for specific end uses. Furthermore, the final selection, when it is made, is often a compromise in which for example, efficacy must be sacrificed for stability or freedom from toxic side-effects.
We have observed that certain mycosporin amino acids which exist in the living tissue of the pacific staghorn coral Acropora Formase are functional UV absorbing agents in corals inhabiting the shallow water, coral reef environment. While these appear to be potentially attractive as commercial UV agents, their utility is questionable because of the difficulty of isolating them from their biological sources and due also to their lack of adequate chemical stability.
We have now discovered that we can prepare certain synthetic analogues of those natural materials, which preserve their characteristic UV-absorbing chromophore within a chemically stable host structure.
The chromophore has the structure:
Figure imgf000005_0001
Surprisingly we have found, in particular, that the oxygen subsitutent at the 2 position is fundamental to the UV absorption characteristics UV compounds of the invention. Thus for example it has been observed that certain compounds containing the above chromophore have an absorption maximum at 305-340 nm. When analogous carbonylsare prepared in which there is no oxygen function at the 2 position (e.g. ethyl 3-octylamino-2-butencate) then the absorption maximum drops to about 285 nm, which is significantly below the abovementioned useful absorption range achieved by UV compounds of this invention. Preferred novel UV absorbing compounds of the invention, which are particularly useful in sunscreens are of formula (2) or (3) below:
Figure imgf000006_0001
wherein R1 is selected from hydrogen, alkyl or alkenyl;
NR2 is an amino group or a secondary or tertiary amine moiety in which the N atom bears either one or two unsubstituted or substituted alkyl, aryl or alkenyl groups which may be the same or different when two are present;
R is a moiety selected from alkyl, substituted alkyl, hydroxyl, carboxylic acid, ester or ether at positions 4, 5 or 6 on the ring;
n is 0-4. As mentioned hereinabove , the oxygen atom at the 2- position on the ring structure is a characteristic feature of all of our novel compositions.
When the substituent R 1 is alkyl or alkenyl, it may be a straight or branched chain, which in turn may bear further substituent groups or be interrupted by a hetero-atom. For example R1 may be methyl, ethyl, propyl, methoxy methyl or methoxy ethyl. It may also be cyclic, for example it may be cyclohexly. Our most preferred compositions are those in which R1 is an alkyl chain containing 1 - 4 carbon atoms.
In its simplest form, -NR2 is a amino group. One or both of the hydrogen atoms of that group may be replaced as described hereinabove by the same or different substituents selected from alkyl, aryl or alkenyl groups, which may themselves be branched, linear or contain a cyclical structure. The selected substituent may itself contain a further substituent. When both hydrogen atoms are replaced, the substituent groups may together form a carbocyclic or heterocyclic ring system.
Thus suitable components -NR2 are, for example, cyclohexylamino, anilino, undecylamino, hexylamino, octylamino, decylamino, heptylamino, benzylamino, octadecylamino, pentylamino, nonylamino, N-methyl-N-benzylamino, di-butylamino, N-morpholino dodecylamino, phenethylamino, 1,1,3,3 tetramethyl butylamino, N-pyrolidinyl, N-piperidenyl, di-butylamino, N-methyl-N-cyclohexylamino, components of the structures -NHCH2COOCE3, -NHCH (CH3)COOCH3 , -NHCH(CH2OH)COOCH3 and -NHCH(HO-4-C6H4)COOCH3.
Preferably structures are those in which -NR2 is alkylamino, arylamino, amino acid and amino acid ester. When long term stability of the molecule is of major concern, it is most preferred that -NR2 be a disubstituted amino.
The composition of the component R when present, is not usually critical and it is chosen with regard to such factors as, for example, the required solubility of hydrophilic/lipophilic balance of the molecule as a whole. Thus suitable components R are, for example, alkyl, substituted alkyl, hydroxyl, alkoxy, carboxylic acid ester or ester moieties. That is R may be, for example, 5-hydroxyl, 5 carboxylic acid or ester thereof, 5-hydroxymethyl, 5,5-dimethyl, 5-t-butyl and 4,4,6,6-tetramethyl.
Preferred compositions are those in which the component R when present, is methyl or ethyl.
The compounds (4c) below may be prepared by an appropriate standard method of organic synthesis. For example, compounds of this invention may conveniently be prepared via 3-substituted-2-hydroxy-(or 2-alkoxy-)-cycloalk-2-enones (4a, 4b) where the 3-substituent may be a hydroxyl or a a) R1=H ; X =OH,Cl,Br b) R1 = alkyl; X =OH,CI,Br c) R1 = alkyl; X = NR2
Figure imgf000009_0001
(where m = 2 or 3 and R1, NR2 and (R)n are as hereinbefore defined). suitable function which can serve as a leaving group e.g., -C1 or -Br. Compounds (4a) are acidic and can be alkylated at the 2-hydroxyl group with suitable alkylating agents such as dialkyl sulphates, alkyl tosylates or diazoalkanes (when there is no 3-hydroxyl) to give the alkyl derivatives (4b). Compounds (4b) can be reacted with amino compounds to effect a substitution at the 3-position to give compounds (4c). Compounds of structure (4a) may be prepared by a number of routes from various starting materials depending on the desired size and substitution of the carbocycle. The following procedures are illustrative. Reduction of 1,2,3 trihydroxy benzenes gives 2,3 dihydroxy cyclohex-2-enones and halogenation with copper chloride gives 3-chloro-2-hydroxy-cyclohex-2 enones. These compounds (4a) may then be converted to the compounds of the invention by the methods indicated hereinabove.
One of the potentially most useful applications of these UV agents is their incorporation in sunscreen preparations for skin protection. For this purpose we prefer that the selected UV agent have an absorption maximum in the region of 305-340 nm. In general this will require that the UV compound according to our invention will comprise a six-membered ring as structure (2) since derivatives of the five-membered enaminoketones tend to absorb UV-light in the region of 287-297 nm. Thus, for our purposes as sun-screen agents, we prefer to use compounds according to structure (2).
The UV compounds of the invention are readily compounded by the standard methods of the art into, for example, creams or lotions, making use of conventional emollients, emulsifiers, preservatives, anti-oxidants, perfumes and colouring agents.
By way of illustration only, suitable emollients are, mineral oil, squalene, octyl palmitate, cocoa butter, sesame oil, and pristane, either singly or in combination. Typical emulsifiers including for example, polyoxyethylene (3) olyl ether, polyglyceryl-4-oleate and polysorbate 80. The invention is illustrated by the following examples, in which all parts are given by weight.
Example 1
Preparation of 3-chloro-2-hydroxy-cyclopent-2-enone
Cyclopentanone (16 g, 0.15 mol) and cupric chloride (240 g, 1.5 mol) were refluxed for 1.5 h in 800 ml of a 50% solution of dioxane in water. This was allowed to cool, then water (400 ml) was added, filtered and extracted 3-5 times with diethyl ether (total 2.0 1). The organic phase was backwashed with water (200 ml), dried over sodium sulphate and evaporated to collect crude product, mp 130°. The crude material was dissolved in a large quantity of dichloromethane, treated with charcoal and filtered. This solution was evaporated to a suspension then filtered to collect the product as pale yellow crystals, mp 140-141°C.
Example 2
Preparation of 3-bromo-2-hydroxy-cyclopent-2-enone
Water (200 ml) containing 80 ml of 48% hydrogen bromide and cyclopentanone (67.2 g, 0.8 mol) was cooled to 5°C. Bromine (123.6 g, 2.4 mol) was added dropwise over 6 h while maintaining the temperature between 5-15°C. The reaction vessel was then left overnight in a large water bath. The resulting orange solution was added to water (1.5 1) and the organic phase separated. This was vigorously stirred in water (2 1) for 48 h. The aqueous phase was continuously extracted with diethyl ether. The extracts were dried over sodium sulphate and evaporated to collect a brown solid, mp 148°.
Example 3
Preparation of 3-chloro-2-methoxy-cyclopent-2-enone
3-Chloro-2-hydroxy-cyclopent-2-enone (2.8 g, 21.13 mmol) was dissolved in methanol (15 ml) and cooled to 0°C. To this mixture, an ethereal solution of diazomethane (42 mmol) was added portionwise with swirling. This was then allowed to warm to room temperature overnight. Polymeric material was then filtered off and the filtrate evaporated under reduced pressure to leave a yellow oil. This was purified by column chromatography on silica gel using 30:70 dichloromethane: petroleum spirit resulting in a pale yellow oil. Example 4 Preparation of 3-cyclohexylamino-2-methoxy-cyclopent-2-enone
Into a 5 ml glass vial, fitted with a rubber septum and under an atmosphere of nitrogen were placed 3-chloro-2-methoxycyclopent-2-enone (0.5 g, 3.4 mmol), triethylamine (0.48 ml, 3.4 mmol) and cyclohexylamine (0.51 g, 5.1 mmol). This was heated at 30°C for 42 h. The contents were then dissolved in methanol (3 ml) and treated with one equivalent of sodium hydroxide dissolved in the minimum amount of methanol. The solvent and triethylamine were evaporated and the residue dissolved in dichloromethane, then filtered. The filtrate was evaporated to give crude product in near quantitative yield. The oil was distilled by Kugelrohr distillation giving a pale yellow oil which crystallized when triturated with diethyl ether, mp 105-106°.
Examples 5 to 12
The compounds described in Table 1 and Table 2 below were prepared following essentially the same procedure described in Example 4.
Figure imgf000015_0001
Figure imgf000016_0001
Figure imgf000017_0001
Figure imgf000018_0001
Example 13
Preparation of 2,3-hydroxy-cyclohex-2-enone
Pyrogallol (1,2,3-trihydroxybenzene, 75 g; 0.6 mol) was charged in a 1 liter hydrogenation bomb and a cooled (0°) solution of aqueous sodium hydroxide (24 g in 150 ml H2O ) was added under nitrogen. Raney nickel catalyst ( approx. 4 g; activity W-2) was admixed under nitrogen. Hydrogenation was conducted at room temperature for 24 hours at a pressure of 1000 psi H2 with constant shaking. The resulting mauve coloured solution was filtered through celite (diatomaceous earth) to remove the nickel catalyst and the filtrate was cooled to -5°C. Acidification to pH 3-4 yielded a silky greywhite solid. The solid was collected by filtration, dried, and recrystalization from benzene gave a pale yellow solid, m.p. 114-115°. Evaporation of the filtrate to a volume of 100 mis and continuous extraction (24 h) with benzene afforded an additional quantity of dihydropyrogallol (2,3-dihydroxycyclohex-2-enone) after drying (Na2 SO4) and crystalization from benzene.
Example 14
Preparation of 3-cyclohexyla_mino-2-hydroxy-cyclohex-2-enone
2,3-Dihydroxy-cyclohex-2-enone (3.8 g; 0.03 mol) was dissolved in chloroform (100 ml) and cooled to 5°C. Cyclonexylamine hydrochloride (4.1 g; 0.03 mol) was added with stirring under nitrogen. Triethylamine (dried over molecular sieves) was added dropwise to pH 6.6 and the mixture refluxed for 16 hours during which the pH was adjusted to maintain between 6.2 and 6.7. The progress of the reaction was monitored by UV-spectroscopy. At completion of the condensation reaction the chloroform was removed under reduced pressure and the residue extracted into ether. The product was obtained on evaporation of the ether and vacuum distillation (190-200°/100 mTorr).
Examples 15 to 17
The compounds described in Table 3 and Table 4 below were prepared following essentially the same proceedures described in Example 14.
Figure imgf000021_0001
Figure imgf000022_0001
Example 18
Preparation of 3-hydroxy-2-_methoxy-cyclohex-2-enone
2,3-Dihydroxy-cyclohex-2-enone (15 g) was dissolved in 4N NaOH (45 ml) and cooled to 5°C. Dimethyl sulfate (18 ml; freshly distilled and stored over KOH pellets) was added dropwise with vigorous stirring while maintaining the internal temperature below 10°C. The reaction was maintained above pH 7 throughout the addition while under an atmosphere of nitrogen. A further quantity of 4N NaOH (45 ml) was added after the addition of dimethyl sulfate was completed and the reaction was allowed to stir overnight (16 h) at room temperature. The mixture was cooled to 5°C and acidified to congo red with 4N H2SO4 while still under nitrogen. The resulting yellow solution was evaporated to ca. half-volume andthe product removed by continuous extraction (48 h) with ether. The ether extract was dried (Na2SO4) and evaporation afforded a yellow oil which crystalized under vacuum (50 mTorr). Recrystalization from benzene:hexane gave 3-hydroxy-2methoxy-cyclohex-2-enone as pale yellow needles, m.p. 109¬110°C.
Example 19
Preparation of Methyl N-(2-m_ethoxy-cyclohex-2-enone-3-yl)glycinate
3-Hydroxy-2-methoxy-cyclohex-2-enone (4.26 g; 0.03 mol) was dissolved in chloroform (100 ml) and cooled to 5°C. Methyl glycinate hydrochloride (3.77 g; 0.03 mol) was added with stirring under nitrogen. Triethylamine (dried over molecular sieves) was added dropwise until pH 6.6. The mixture was refluxed for 72 h during while the pH was maintained between 5.7-6.6. Progress of the reaction was determined by UV-spectroscopy. At completion of the condensation reaction the chloroform was removed under vacuum and the residue was chromatographed on silica-gel with light petroleum (b.p. 60-80°) and methanol (10%). The fraction containing the product was evaporated and the residue crystalized from light petroleum (b.p. 60-80°): chloroform to give the product as brown crystals which decomposed rapidly on exposure to air or while in solution.
Examples 20 - 24
The compounds described in Table 5 and Table 6 below were prepared following essentially the proceedures described in Example 19.
Figure imgf000025_0001
Figure imgf000026_0001
Figure imgf000027_0001
Example 25
Preparation of 2-methoxy-3-pentylamino-cyclohex-2-enone
3-Hydroxy-2-methoxy-cyclohex-2-enone (5.69 g; 0.04 mol) was admixed with n-pentylamine (5.23 g; 0.06 mol). The reaction mixture was heated to reflux with stirring under an atmosphere of nitrogen for 24 hours. Progress of the condensation reaction was determined by UV-spectroscopy. At completion of the reaction excess amine was removed under reduced pressure and the residue distilled between 136-142°C at a pressure of 65 mTorr. The product distillate was refractionated using a micro-distillation apparatus at equivalent temperature and pressure.
Examples 26 - 42
The compounds described in Table 7 and Table 8 below were prepared following essentially the proceedures described in Example 25.
Figure imgf000029_0001
Figure imgf000030_0001
Figure imgf000031_0001
Figure imgf000032_0001
Figure imgf000033_0001
Figure imgf000034_0001
Figure imgf000035_0001
Figure imgf000036_0001
Example 44
Preparation of 2-ethoxy-3-octylaιnino-cyclohex-2-enone
2-Ethoxy-3-hydroxy-cyclohex-2-enone (6.25 g; 0.04 mol) was admixed with n-octylamine (10.28 g; 0.06 mol). The reaction was heated to 140°C for 20 h with vigorous stirring under an atmosphere of nitrogen. Progress of the condensation reaction was determined by UV-spectroscopy. At completion of the condensation reaction the product was obtained by distillation (160-164°C/65 mTorr) and the distillate refractionated in a micro-distillation apparatus.
Example 43
Preparation of 2-ethoxy-3-hvdroxy-cyclohex-2-enone
2,3-Dihydroxy-cyclohex-2-enone (15 g) was dissolved in ethanol (50 ml) and cooled to 5°C in an ice bath. Aqueous 4NNaOH (45 ml) was added to the ethanolic solution under nitrogen. Diethyl sulfate (22 ml) was added dropwise with vigorous stirring while maintaining the internal temperature below 10°C. The reaction was maintained above pH 7 throughout the addition under an atmosphere of nitrogen. A further quantity of 4N NaOH (45 ml) was added after the addition of diethyl sulfate was completed and the reaction allowed to stir at room temperature for 24 h. The organic solvent was removed under reduced pressure. The resulting aqueous solution was cooled to 5°C and acidified to congo red with 4N H2SO4. The product was removed from the aqueous phase by continuous extraction (48 h) with ether. The ether extract was dried (Na2SO4) and evaporation afforded a dark yellow oil which solidified on drying under vacuum (50 mTorr). The product was purified by column chromatography on silica-gel (benzene:ethanol). Evaporation of the solvents gave a light yellow oil which solidified on drying under vacuum. Recrystalisation from benzene:ethanol (charcoal) gave 2-ethoxy3-hydroxy-cyclohex-2-enone as pale yellow needless, m.p. 91¬93°C. Examples 45 - 50
The compounds described in Table 9 and Table 10 below were prepared following essentially the proceedures described in Example 44.
Figure imgf000039_0001
Figure imgf000040_0001
Figure imgf000041_0001
Figure imgf000042_0001
Example 51
Preparation of 5-tertiary-butyl-3-chloro-2-hydroxycyclohex-2-enone
A solution of 4-tertiary-butyl-cyclohexanone (7.71 g, 0.05 mol) and copper (II) chloride dihydrate (131.2 g, 0.75 mol) in water (200 ml) and dioxane (200 ml) was heated under reflux for 2 hours. After cooling to room temperature, the mixture was extracted with ether (2 x 150 ml) and the combined organic extracts were dried (anhydrous magnesium sulphate), then concentrated under reduced pressure. The residue was purified by column chromatography (40-63 μm silica gel) using 30% hexane in dichloromethane as eluant to give 5-tertiary-butyl-3-chloro2-hydroxy-cyclohex-2-enone as a white crystalline solid, mp 85-86°C.
Example 52
Preparation of 5-tertiary-butyl-3-chloro-2-m_ethoxy cyclohex-2-enone
A solution of diazomethane (1.26 g, 0.03 mol) in diethyl ether (90 ml), was added portionwise to an ice cold solution of 5-tertiary-butyl-3-chloro-2-hydroxy-cγclohex-2-enone (2.03 g, 0.01 mol) in methanol (20 ml). After standing for 1 hour at 0°C, then overnight at room temperature, the solution was concentrated under reduced pressure, diluted with diethyl ether (20 ml), filtered and the filtrate concentrated under reduced pressure to leave a colourless oil. Examples 53 - 54
The compounds described in table 11 and table 12 below were prepared following essentially the same procedure described in Example 4.
Figure imgf000044_0001
Figure imgf000045_0001
Example 55
UV-Stability of 2-alkoxy-3-a_mino-cyclohex-2-enones
A selection of 2-alkoxy-3-amino-cyclohex-2-enones were tested for UV-stability and compared with compounds contained in commercial preparations of common use as sun-screening agents. These data are tabulated in Table 13. The apparatus used in this proceedure is outlined by D. S. Berger in "Specification and design of solar ultraviolet simulators" (J. Invest. Derm., 53 (3), 192, 1969) incorporating a Sellotape 636 or 672 filter as replacement for the specified Schott WG 320 filter. A Hitachi 150-20 spectrophotometer was used to record
UV specta and to determine the maximum absorbance. Dilute solutions (~ 3 x 10- 6M) of the selected compounds described in this invention dissolved in isopropyl alcohol were irradiated for periods of time specified in Table 13. The UV spectrum was recorded to determine any shift in the absorption wavelength (λ max) and to determine the absorptivity (A) value. The formation of decomposition products also absorbing at λ max were determined (if any) by HPLC separation using isocratic elution (MeOH : H2O, 80:20; PIC B6, 0.01M, pH 3.0) on a 3 μ microsorb, C-18 reverse-phase column. The samples tested proved to be quite stable (max. loss ~ 3%) and comparable with
2 commercial sunscreens, 2-ethylhexyl N,N-dimethyl-p-benzoate
((A); Escalol 507) and 2-ethylhexyl p-methoxy-cinnamate ((B);
Neo Heliopan UV).
Figure imgf000047_0001

Claims

The claims defining the invention are as follows: 1. An ultra violet light absorbing compound containing the chromophore
Figure imgf000048_0001
2. A compound as claimed in claim 1 having the formula:
Figure imgf000048_0002
(1) (2)
wherein R1 is selected from hydrogen, alkyl or alkenyl; NR2 is an amino group or a secondary or tertiary amine moiety in which the N atom bears either one or two unsubstituted or substituted alkyl, aryl or alkenyl groups which may be the same or different when two are present; R is a moiety selected from alkyl, substituted alkyl, hydroxyl, carboxylic acid, ester or ether at positions 4, 5 or 6 on the ring; n is 0-4.
3. A compound as claimed in claim 2 wherein R is an alkyl group bearing further substituent groups or is an alkyl group interrupted by a hetero-atom.
4. A compound as claimed in claim 2 wherein R1 is methyl, ethyl, propyl, methoxy methyl or methoxy ethyl.
5. A compound as claimed in claim 2 wherein R1 is cyclohexyl.
6. A compound as claimed in claim 2 wherein R1 is an alkyl chain containing 1-4 carbon atoms.
7. A compound as claimed in claim 2 wherein -NR2 is an amino group.
8. A compound as claimed in claim 2 wherein NR2 is a secondary or tertiary amine moiety.
9. A compound as claimed in claim 2 wherein both hydrogen atoms of the amino group are replaced by a substituent groups which may together form a carbocyclic or heterocyclic ring system.
10. A compound as claimed in claim 2 wherein -NR2 is selected from cyclohexylamino, anilino, undecylamino, hexylamino, octylamino, decylamino, heptylamino, benzylamino, octadecylamino, pentylamino. nonylamino, N-methyl-N-benzylamino, di-butylamino, N-morpholino dodecylamino, phenethylamino, 1 , 1 , 3 , 3 tetramethyl butylamino, N-pyrolidinyl, N-piperidenyl, di-butylamino, N-methyl-N-cyclohexylamino, components of the structures -NHCE2COOCH3, -NHCH(CH3)COOCH3, -NHCH (CH2OH)COOCH3, and -NHCH(HO-4-C6H4)COOCH3.
11. A compound as claimed in claim 2 wherein NR2 is alkylamino, arylamino amino acid or amino acid ester.
12. A compound as claimed in claim 2 wherein NR2 is disubstituted amino.
13. A compound as claimed in claim 2 wherein R is selected from 5-hydroxyl 5-carboxylic acid or ester thereof 5-hydroxymethyl, 5,5-dimethyl, 5-t-Jsutyl and 4,4,6,6-tetramethyl.
14. A compound as claimed in claim 2 wherein R is methyl or ethyl.
15. A compound as claimed in claim 1 substantially as herein described with reference to any one of the Examples 1-46.
16. A composition useful for absorbing UV light containing a compound as claimed in any preceding claim.
17. A sunscreen protective composition wherein the active ingredient is a compound as claimed in any preceding claim.
18. A process for preparing an ultra-violet light absorbing compound by the reaction of a compound according to structure 4(b) herein with an amino compound to give a compound according to structure 4(c) herein.
19. A process of preparing a sunscreen protective composition by the incorporation of an ultra violet light absorbing compound according to any one of claims 1-15 into a cream or lotion carrier base.
PCT/AU1985/000242 1984-10-10 1985-10-03 Ultra violet agents WO1986002350A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPG757284 1984-10-10
AUPG7572 1984-10-10
AUPG7681 1984-10-17
AUPG768184 1984-10-17

Publications (1)

Publication Number Publication Date
WO1986002350A1 true WO1986002350A1 (en) 1986-04-24

Family

ID=25642856

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU1985/000242 WO1986002350A1 (en) 1984-10-10 1985-10-03 Ultra violet agents

Country Status (6)

Country Link
EP (1) EP0196328A4 (en)
AU (1) AU587211B2 (en)
ES (1) ES8801184A1 (en)
GR (1) GR852436B (en)
WO (1) WO1986002350A1 (en)
ZA (1) ZA857767B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2803201A1 (en) * 1999-12-30 2001-07-06 Gelyma Algal extracts containing amino acid analogs of mycosporin are useful as dermatological protecting agents against ultraviolet radiation
WO2015195546A1 (en) * 2014-06-17 2015-12-23 TopGeniX, Inc. Topical formulations for uv protection
US9234204B2 (en) 2012-08-07 2016-01-12 TopGeniX, Inc. Topical composition comprising transformed bacteria expressing a compound of interest

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4371603A (en) * 1980-12-30 1983-02-01 Polaroid Corporation Amino hydroxy cyclohexenone developing agents
US4515982A (en) * 1981-12-28 1985-05-07 Basf Aktiengesellschaft Aminoreductones

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3690872A (en) * 1970-12-02 1972-09-12 Eastman Kodak Co Photographic developing process with amino hydroxy cycloalkenone
US4514383A (en) * 1982-05-05 1985-04-30 Johnson & Johnson Baby Products Company Sunscreen compositions containing vinylogous amides
DE3312425A1 (en) * 1983-04-07 1984-10-11 Basf Ag, 6700 Ludwigshafen FABRIC MIXTURES WITH GROWTH-PROMOTING AND PERFORMANCE-IMPROVING EFFECT, FEED AND DRINKING LIQUIDS THAT CONTAIN LOW QUANTITIES OF THESE MIXTURES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4371603A (en) * 1980-12-30 1983-02-01 Polaroid Corporation Amino hydroxy cyclohexenone developing agents
US4515982A (en) * 1981-12-28 1985-05-07 Basf Aktiengesellschaft Aminoreductones

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0196328A4 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2803201A1 (en) * 1999-12-30 2001-07-06 Gelyma Algal extracts containing amino acid analogs of mycosporin are useful as dermatological protecting agents against ultraviolet radiation
US9234204B2 (en) 2012-08-07 2016-01-12 TopGeniX, Inc. Topical composition comprising transformed bacteria expressing a compound of interest
US9453232B2 (en) 2012-08-07 2016-09-27 TopGeniX, Inc. Topical composition comprising transformed bacteria expressing a compound of interest
US9868957B2 (en) 2012-08-07 2018-01-16 TopGeniX, Inc. Topical composition comprising transformed bacteria expressing a compound of interest
WO2015195546A1 (en) * 2014-06-17 2015-12-23 TopGeniX, Inc. Topical formulations for uv protection
JP2017519823A (en) * 2014-06-17 2017-07-20 トップジェニックス, インク.Topgenix, Inc. Topical formulation for UV protection
EP3164196A4 (en) * 2014-06-17 2017-12-06 Topgenix, Inc. Topical formulations for uv protection
US10064797B2 (en) 2014-06-17 2018-09-04 TopGeniX, Inc. Topical formulations for UV protection

Also Published As

Publication number Publication date
ES8801184A1 (en) 1986-11-16
GR852436B (en) 1986-02-10
ES547726A0 (en) 1986-11-16
ZA857767B (en) 1986-05-28
AU587211B2 (en) 1989-08-10
AU4968985A (en) 1986-05-02
EP0196328A4 (en) 1987-03-12
EP0196328A1 (en) 1986-10-08

Similar Documents

Publication Publication Date Title
US4999186A (en) Novel sunscreen agents, sunscreen compositions and methods for preventing sunburn
US4937370A (en) Novel chromophores, sunscreen compositions and methods for preventing sunburn
US4585597A (en) 3-benzylidene-camphors, process for their preparation and their use in protection against UV rays
US4522808A (en) Anti-sunburn compositions containing 2-phenyl-indole derivatives
US5501850A (en) Use of benzimidazole derivatives as light protection filters
US5210275A (en) Chromophores, sunscreen compositions and methods for preventing sunburn
US5175340A (en) New liposoluble unsaturated benzalmalonate derivatives and their use as absorbers for ultraviolet radiation in cosmetics
GB2189482A (en) Benzoic benzopyranyl and benzothiopyranyl compounds
GB2149789A (en) Ultraviolet absorbing chalcone derivative
EP0251398B1 (en) Novel chromophores, sunscreen compositions and methods for preventing sunburn
WO1997000851A1 (en) Chemical compounds and methods of production thereof
JPH07503963A (en) Triazine derivative with UV filter properties
US5041282A (en) Method for protecting the skin from UVA and UVB rays
US5718906A (en) Light-stable cosmetic composition
US4070450A (en) Sunscreening compound and method
US5160731A (en) Sunscreen agents, sunscreen compositions and methods for preventing sunburn
AU587211B2 (en) Ultra violet agents
US5144081A (en) Dialkoxybenzylidene-camphor derivatives
JPS6396120A (en) Anti-suntan cosmetic
JPS61140543A (en) 4-methoxy-2'-carboxydibenzoylmethane and salt thereof
JPS61293965A (en) Indoline derivative,manufacture and cosmtic sun-screening agent containing same
US5243064A (en) Chromophores, sunscreen compositions and methods for preventing sunburn
GB2105190A (en) Light-screen compositions
US3953589A (en) Method for protecting human skin from ultraviolet radiation
US5229107A (en) Sunscreen agents, sunscreen compositions and methods for preventing sunburn

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR DK JP NO US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1985905185

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1985905185

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1985905185

Country of ref document: EP